| Identification | Back Directory | [Name]
GNE-431 | [CAS]
1433820-83-7 | [Synonyms]
GNE-431
Pyrazino[1,2-a]indol-1(2H)-one, 3,4,6,7,8,9-hexahydro-2-[3-(hydroxymethyl)-4-[8-[(4,5,6,7-tetrahydro-5-methylpyrazolo[1,5-a]pyrazin-2-yl)amino]imidazo[1,2-b]pyridazin-6-yl]-2-pyridinyl]- | [Molecular Formula]
C30H32N10O2 | [MDL Number]
MFCD32204434 | [MOL File]
1433820-83-7.mol | [Molecular Weight]
564.64 |
| Hazard Information | Back Directory | [Uses]
GNE-431 is a potent, selective and noncovalent “pan-BTK” inhibitor against C481R, T474I and T474Ms mutants. GNE-431 shows potency against wild-type BTK (IC50= 3.2 nM) and potency against C481S mutant (IC50= 2.5 nM). GNE-431 is proming for rasearch of haematological disorders and autoimmune diseases[1][2]. | [References]
[1] Tasso B, et al. The Development of BTK Inhibitors: A Five-Year Update. Molecules. 2021 Dec 6;26(23):7411. DOI:10.3390/molecules26237411
[2] Brullo C, et al. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. Int J Mol Sci. 2021 Jul 16;22(14):7641. DOI:10.3390/ijms22147641 |
|
|